ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Guided Biopsy for Mapping Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Prostatectomy

First Posted Date: 2009-11-03

Last Posted Date: 2014-02-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01007214

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: cetuximab with irinotecan

First Posted Date: 2009-10-29

Last Posted Date: 2015-10-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01004159

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Clofarabine

First Posted Date: 2009-10-29

Last Posted Date: 2016-06-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01003678

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Phase 1

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer
Recurrent Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: everolimus
Other: laboratory biomarker analysis
Other: pharmacogenomic studies
Other: pharmacological study

First Posted Date: 2009-09-22

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00981162

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Cancer of Prostate
Prostate Neoplasms
Neoplasms, Prostatic
Prostatic Cancer
Cancer of the Prostate
Neoplasms, Prostate

Interventions: Biological: androgen ablation (AA)
Biological: DC1 vaccine

First Posted Date: 2009-09-02

Last Posted Date: 2020-11-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00970203

Locations: 🇺🇸
University of Pittsburgh Cancer institute, Pittsburgh, Pennsylvania, United States

Acceptability of Less Harmful Alternatives to Cigarettes

Not Applicable

Completed

Conditions: Head and Neck Cancer
Liver Cancer
Pancreatic Cancer
Kidney Cancer
Leukemia
Tobacco Use Disorder
Bladder Cancer
Esophageal Cancer
Cervical Cancer
Gastric Cancer

Interventions: Behavioral: telephone-based intervention
Drug: nicotine replacement therapy
Other: informational intervention
Other: internet-based intervention
Other: questionnaire administration

First Posted Date: 2009-08-12

Last Posted Date: 2017-02-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 67

Registration Number: NCT00957424

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

Phase 2

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: vorinostat
Other: pharmacological study

First Posted Date: 2009-07-20

Last Posted Date: 2014-06-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00942266

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer

Not Applicable

Terminated

Conditions: Head and Neck Cancer

Interventions: Biological: cetuximab
Radiation: stereotactic body radiation therapy

First Posted Date: 2009-05-01

Last Posted Date: 2016-04-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00891904

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

Not Applicable

Completed

Conditions: Prostate Adenocarcinoma

Interventions: Dietary Supplement: Cholecalciferol
Other: Laboratory Biomarker Analysis
Other: Patient Observation
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2009-04-24

Last Posted Date: 2021-10-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 132

Registration Number: NCT00887432

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Not Applicable

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Angioimmunoblastic T-cell Lymphoma
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Diffuse Large Cell Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: anti-thymocyte globulin

First Posted Date: 2009-03-05

Last Posted Date: 2019-11-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00856388

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy